Dr Reddy’s Laboratories invests Rs 565 crore in Russian subsidiary, acquiring 45.19% stake for working capital needs.

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

Dr. Reddy's Laboratories has kicked off FY26 with double-digit growth. M.V. Ramana, CEO of Branded Markets (India & Emerging Markets), breaks down how the pharma major is evolving its strategy beyond ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

The latest update is out from Dr Reddy’s Laboratories ( (RDY) ).

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported profit of $165 million in its fiscal first quarter. On a per-share basis, the Hyderabad, India ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr Reddy's Laboratories posted a 1% rise in net profit to Rs 1,410 crore for the June quarter, with revenue climbing to Rs 8,545 crore. Growth stemmed from branded markets and the Nicotine Replacement ...